Posted by Michael Wonder on 25 Jun 2024
Takeda announces approval of Livtencity (maribavir) in Japan for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies
24 June 2024 - Livtencity is the first and only post-transplant anti-CMV treatment approved in Japan that targets/inhibits UL97 protein kinase.
Takeda today announced that Livtencity (maribavir) has been approved by the Japanese MHLW for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.
